DJ Hardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative Hardman & Co Research Hardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
DJ Hardman & Co Q&A on H&T Group (HAT): Unique opportunities for strong, profitable growth Hardman & Co Research Hardman & Co Q&A on H&T Group (HAT): Unique opportunities for strong, profitable growth
DJ Hardman & Co Q&A on Apax Global Alpha (APAX): 2022 results adding value to companies leads to outperformance Hardman & Co Research Hardman & Co Q&A on Apax Global Alpha (APAX): 2022 results adding
DJ Hardman & Co Research on Oakley Capital Investments Ltd (OCI): 2022: NAV returns driven by EBITDA growth Hardman & Co Research Hardman & Co Research on Oakley Capital Investments Ltd (OCI): 2022:
DJ Hardman & Co Research on Apax Global Alpha (APAX): Outperformance by adding value to companies Hardman & Co Research Hardman & Co Research on Apax Global Alpha (APAX): Outperformance by adding